Otylosc - problem spoleczny i leczniczy

• Autorzy: Klosiewicz-Latoszek L.

Warianty tytułu

EN

Obesity - social and therapeutic problem

• Języki publikacji: PL

Słowa kluczowe

PL

choroby czlowieka; otylosc; zywienie czlowieka; dieta; leki; leczenie chirurgiczne

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2004
• Tom: 31
• Numer: 3
• Opis fizyczny: s.281-289,tab.,bibliogr.

Twórcy

autor

Klosiewicz-Latoszek L.

• Instytut Zywnosci i Zywienia w Warszawie, Warszawa

Bibliografia

• 1. International Union of Nutritional Sciences. The global challenge of obesity and the International Obesity Task Force. Available from: URL: http:// www.iuns.org/features/obesity/obesity.htm (Accessed 30 October 2003).
• 2. World Health Organization Health Topics. Nutrition. Available from: URL: http:// www.who.int/nut/obs.htm (Accessed 24 October 2003).
• 3. World Health Organization. Obesity: preventing and managing the global epidemic. WHO obesity technical report series 894. Geneva, Switzerland: World Health Organization, 2000.
• 4. James ET., Leach R., Kalamara E., Shayeghi M.: The worldwide obesity epidemic. Obes. Res., 2001, 9 (Suppl. 4), 228S-233S.
• 5. Flegal K.M., Caroll M.D., Kuczmarski R.J., et al.: Overweight and obesity among adults: United States: prevalence and trends, 1960-1994. Int. J. Obes. Relat. Metab. Disord., 1998, 22, 39-47.
• 6. European Health Report 2002.
• 7. www.natpol.pl.
• 8. Zdrojewski T., Babińska Z., Bandosz P, i in.: Związek nadwagi i otyłości z podwyższonymi wartościami ciśnienia tętniczego w badaniach reprezentatywnych grup dorosłych Polaków w 1997 i 2002 r. (NATPOL II, NATPOL III). Med. Metab., 2002, 4 (Suppl.), 32.
• 9. Stan zdrowia ludności Warszawy w roku 2001. Program POL-MONICA BIS Warszawa. Wyd. Instytut Kardiologii w Warszawie, Warszawa, 2002.
• 10. Must A., Spadano J., Coakley EH., et al.: The diseases burden associated with overweight and obesity. J. Am. Med. Assoc., 1999, 282, 1523-9.
• 11. Jousilahti P., Tuomilehto J., Varitainen E., et al.: Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation, 1996, 93, 1372-9.
• 12. Lapidus L., Bengtsson C., Larsson B., et al.: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br. Med. J. (Clin. Res. Ed.), 1984, 289, 1257-61.
• 13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc., 2001, 285, 2486-97.
• 14. De Backer G., Ambrosioni E., Borch-Johnsen K., et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societes on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J., 2003, 24, 1601-10.
• 15. Grzybek A., Kłosiewicz-Latoszek L., Targosz U.: Changes in the intake of vitamins and minerals by men and women with hyperlipidemia and overweigt during dietetic treatment. Eur. J. Clin. Nutr., 2002, 56, 12, 1162-1168.
• 16. Pachocka L., Grzybek A., Targosz U., et al.: Effect of a low-energy diet on body composition, insulin, fibrinogen and tPA concentration i obese subjects. Proc. Germ. Nutr. Soc., 2002, 4, 42-44.
• 17. Pachocka L., Kíosiewicz-Latoszek L.: Zmiany w spożyciu wybranych witamin u osób dorosłych z nadwagą i otyłością po zastosowaniu diety niskoenergetycznej. Roczn. PZH, 2002, 53, 3, 243-52.
• 18. Case C.C., Jones P.H., Nelson K., et al.: Impact of weight loss on the metabolic syndrome. Diabetes Obes. Metab., 2002, 4, 407-14.
• 19. Noakes M., Clifton P.: Weight loss, diet composition and cardiovascular risk. Curr. Opin. Lipidol., 2004, 15, 31-35.
• 20. Stern L., Igbal N., Seshadri P., et al.: The effects of low-carbohydrate versus conventional weight loss diet in severely obese, adults: one-year follow-up of a randomized trial. Arm. Intern. Med., 2004, 140, 778-785.-
• 21. Kłosiewicz-Latoszek L.: Efekty diet niskotłuszczowych i niskowęglowodanowych. Żyw. Człow. Metab., (w druku).
• 22. Velussi M., Monte A.D., Cernigoi A.M.: Therapeutic benefit of benfluorex in type II diabetic patients on diet regimen alone. J. Diabetes Complications, 1996, 10, 261-266.
• 23. McNeely W, Goa K.L.: Sibutramine: a review of its contribution to the management of obesity. Drugs, 1998, 56, 1093-1124.
• 24. National Task Force on The Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996, 276, 1907-1915.
• 25. Redmon J., Raate S., Reck K.P. et al.: One-year outocome of a combination of weight loss therapies for subjects with type 2 diabetes. Diabetes Care, 2003, 26, 2505-11.
• 26. McNeely W., Benfield P.: Orlistat. Drugs 1998, 56, 241-249.
• 27. Davidson M.H., Hauptman J., DiGirolamo M., et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281, 235-242.
• 28. Hollander P.A, Elbein S.C, Hirsch I.B, et al.: Role of orlistat in the treatment of obese patients with 2 diabetes: a 1-year randomized double-blind study. Diabetes Care, 1998, 21, 1288-1294.
• 29. Torgerson J.S, Hauptman J, Boldrin M.Nt, Sjostrom L.: Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27, 155-161.
• 30. National Institutes of Health Consensus Development Conference. Gastrointestinal surgery for severy obesity. Am. J. Clin. Nutr, 1992, 55, 487-619.
• 31. MacDonald K.G, Long S.D., Swanson M.S., et al.: The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J. Gastrointest. Surg, 1997, 1, 213-220.
• 32. Mun E.C, Blackburn G.L, Matthews J.B.: Current status of medical and surgical therapy for obesity. Gastroenterology, 2001, 120, 669-681.
• 33. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med, 2002, 346, 393-403.
• 34. Toumilehto J, Lindstrom J, Eriksson J.G, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med, 2001, 344, 1343- 50.
• 35. Dixon J.B, O'Brien P.E.: Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care, 2002, 25, 358-363.
• 36. Sjostrom C.D, Lissner L, Wedel H, Sjostrom L.: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study. Obesity Res, 1999, 7, 477-85.
• 37. Herbst C.A, Hughes T.A, Gwynne J.T, et al.: Gastric bariatric operation in insulin-treated adults. Surgery 1984, 95, 209-13.
• 38. Gleysteen J.G, Barboriak J.J, Sasse E.A.: Sustained coronary risk factor reduction after gastric bypass form morbid obesity, Am. J. Clin. Nutr, 1990, 51, 774-78.
• 39. Jung R.T.: Obesity as a disease. Br. Med. Bull, 1997, 53, 307-21.